Story timeline
1 updatesMerger Talks Report
AstraZeneca shares dropped 7% after reports revealed discussions over a potential $400 billion merger with Bristol Myers Squibb. The Financial Times reported that talks between the pharmaceutical giants have spanned several months.
updates
AstraZeneca Shares Fall 7% Following $400B Merger Report
AstraZeneca shares dropped 7% after reports revealed discussions over a potential $400 billion merger with Bristol Myers Squibb. The Financial Times reported that talks between the pharmaceutical giants have spanned several months.